Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Seeks Silver Lining In Series Of Regulatory Setbacks

Executive Summary

Wyeth believes that offering a lower dose of its serotonin-norepinephrine reuptake inhibitor Pristiq will better position the drug to compete in the major depressive disorder market

You may also be interested in...



Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose

Approval of Wyeth's Pristiq (desvenlafaxine) comes at the lower dose that was submitted late in the review process and with a request for a postmarketing study to determine if even lower doses would be effective

Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose

Approval of Wyeth's Pristiq (desvenlafaxine) comes at the lower dose that was submitted late in the review process and with a request for a postmarketing study to determine if even lower doses would be effective

Wyeth’s Hot Flash: Pristiq “Approvable” Delays Vasomotor Claim At Least A Year

Building a stable of next-generation women's health products is not coming easily to Wyeth. The drug maker received an "approvable" letter July 23 for its Effexor XR follow-on Pristiq for treatment of vasomotor symptoms of menopause, including night sweats and hot flashes

Related Content

UsernamePublicRestriction

Register

PS048291

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel